BRIEF⁠—Allogene Therapeutics names Timothy Moore as chief technical officer

US biotech Allogene Therapeutics has announced the appointment of Timothy Moore as its executive vice president, chief technical officer, effective April 24, 2023.

The selection of Mr Moore, the former EVP, technical operations of Gilead Sciences’ Kite Pharma unit responsible for the global development of two of the most commercially successful autologous CAR T manufacturing processes in the industry, reinforces the company’s mission to being the first to bring an AlloCAR T product to market.

Mr Moore succeeds Alison Moore, who intends to serve as a consultant to Allogene.

“As we look ahead to what could be the industry’s first regulatory submission for an allogeneic CAR T product, we are thrilled to welcome Tim Moore to our team. Tim is a cell manufacturing pioneer, and as a valued colleague during our days together at Kite, there is no one more qualified to lead this critical function at this time. Once again, we both look forward to bringing to patients the next generation CAR T,” said David Chang, president, chief executive and co-founder of Allogene.